Stevanato Group, an Italy-based company that produces glass primary packaging and a provider of integrated capabilities for drug delivery systems, has signed a contract with Bexson Biomedical Inc, a research stage company developing a subcutaneous ketamine treatment platform for pain management and mental health disorders, it was reported on Monday.

The contract has been signed to produce a customised version of the SG EZ-be Pod, a wearable drug delivery device, for Bexson's proprietary ketamine formulation, BB106.

Both firms are working together to develop a small wearable, and programmable device, leveraging Stevanato Group's experience in contract manufacturing and medical device innovation. This technology is to couple with Bexson's ketamine therapy to provide patients with non-opioid treatment for chronic and acute pain types.